• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Reumatologia >Effects of leflunomide treatment on pro-inflammatory mediators in rheumatoid arthritis patients
【24h】

Effects of leflunomide treatment on pro-inflammatory mediators in rheumatoid arthritis patients

机译：来氟米特治疗对类风湿关节炎患者促炎介质的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objective of the study was to investigate the effects of LEF on disease activity and pro-inflammatory mediators during the first 6 months of therapy. We analyzed the course of LEF therapy of 37 RA patients (pts). In 31 pts (83.3%) LEF treatment was continued for at least 6 months; the therapy was interrupted in 6 pts (16.2%) due to adverse events or non-satisfactory clinical effect. Clinical and laboratory data were determined at weeks 0, 4, 12 and 24: disease activity score (DAS 28), C reactive protein (CRP), erythrocyte sedimentation rate (ESR), haemoglobin (HB), erythrocyte (ERY) and platelet (PLT) count, serum concentrations of albumin, interleukin 6 (IL-6), soluble interleukin 6 receptor (sIL-6R), serum amyloid A (SAA) and osteoprotegerin (OPG). The mean value of DAS28 decreased constantly after treatment. During the follow-up mean values of CRP, ESR and PLT count significantly decreased and mean concentrations of albumin, Hb and ERY count significantly increased between week 0 and consecutive weeks. The mean serum concentration of IL-6 decreased significantly between week 0 and weeks 4 and 12 (p<0.01). The mean serum concentration of sIL-6R decreased significantly between weeks 0 and 4 (p=0.03). SAA concentrations were very high in our pts at baseline and decreased constantly in the following weeks 4, 12 and 24 (p<0.01). OPG concentrations were higher at week 4, 12 and 24 with statistical significance between weeks 0 and 4 (p<0.05). Leflunomide therapy in RA pts induces clinical improvement which is connected with significant reduction of SAA and pro-inflammatory cytokine concentrations.
机译：该研究的目的是研究在治疗的前6个月中LEF对疾病活动性和促炎介质的影响。我们分析了37名RA患者的LEF治疗过程（点）。 LEF持续治疗31分（83.3％）至少6个月;由于不良事件或临床效果不理想，治疗中断了6分（16.2％）。在第0、4、12和24周确定临床和实验室数据：疾病活动评分（DAS 28），C反应蛋白（CRP），红细胞沉降率（ESR），血红蛋白（HB），红细胞（ERY）和血小板（ PLT）计数，白蛋白，白介素6（IL-6），可溶性白介素6受体（sIL-6R），血清淀粉样蛋白A（SAA）和骨保护素（OPG）的血清浓度。治疗后DAS28的平均值不断下降。在随访期间，在第0周至连续几周之间，CRP，ESR和PLT计数的平均值显着降低，白蛋白，Hb和ERY计数的平均浓度显着升高。 IL-6的平均血清浓度在第0周，第4周和第12周之间显着降低（p <0.01）。 sIL-6R的平均血清浓度在第0周和第4周之间显着降低（p = 0.03）。 SAA浓度在基线时非常高，在接下来的第4、12和24周中持续下降（p <0.01）。 OPG浓度在第4、12和24周较高，在第0和4周之间具有统计学意义（p <0.05）。 RA pt中的来氟米特疗法可引起临床改善，这与SAA和促炎细胞因子浓度的显着降低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号